Is Neuraxis Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Neuraxis Inc (NRXS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Neuraxis Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neuraxis Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Neuraxis Inc?

Muslim investors may consider investing in Neuraxis Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Neuraxis Inc classified as HALAL?

Musaffa determines the Shariah status of Neuraxis Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Neuraxis Inc updated?

The Shariah compliance status of Neuraxis Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Neuraxis Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Neuraxis Inc?

You can check the latest Shariah compliance status of Neuraxis Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NRXS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: March 24, 2026

Report Source: 2025 Annual Report

Neuraxis Inc. Stock Analysis NRXS

United States Health Care Micro Cap Report: 2025 Annual

NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 24 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.

Key Statistics of Neuraxis Inc (NRXS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$7.70$8.29

Today's Open

$8.29

Volume

114.07K

P/E Ratio (TTM)

52 Week Range

$2.07$9.33

Market Cap

99.98M

Avg. Volume

204.81K

Dividend Yield

Financial Metrics & Statements of Neuraxis Inc (NRXS)

FAQ's for Neuraxis Inc (NRXS)

According to Musaffa’s Shariah screening methodology, Neuraxis Inc (NRXS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.